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Abstract: Various estrogen analogs were synthesized and tested for
binding to human ERα using a fluorescence polarization displacement assay.
Binding affinity and orientation were also predicted using docking calculations.
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Docking was able to accurately predict relative binding affinity and orientation
for estradiol, but only if a tightly bound water molecule bridging
Arg394/Glu353 is present. Di-hydroxyl compounds sometimes bind in two
orientations, which are flipped in terms of relative positioning of their
hydroxyl groups. Di-hydroxyl compounds were predicted to bind with their
aliphatic hydroxyl group interacting with His524 in ERα. One nonsteroid-based
dihdroxyl compound was 1000-fold specific for ERβ over ERα, and was also
25-fold specific for agonist ERβ versus antagonist activity. Docking predictions
suggest this specificity may be due to interaction of the aliphatic hydroxyl
with His475 in the agonist form of ERβ, versus with Thr299 in the antagonist
form. But, the presence of this aliphatic hydroxyl is not required in all
compounds, since mono-hydroxyl (phenolic) compounds bind ERα with high
affinity, via hydroxyl hydrogen bonding interactions with the ERα
Arg394/Glu353/water triad, and van der Waals interactions with the rest of
the molecule.

Keywords: Estrogen receptor, Docking, Phenolic, Breast cancer, Endocrine
disruptor

1. Introduction
Estrogen receptor-α (ERα) is a 595-residue, 66 kDa protein with a
ligand binding domain of 245 residues (28 kDa). ERα, along with
estrogen receptor-β (ERβ), belongs to the nuclear hormone family of
intracellular receptors. It is one of the two principal receptors
responsible for binding the endogenous estrogen, 17β-estradiol (E2),
shown in Figure 1.1 In the nucleus, ER binds to DNA as a dimer,
recruiting coactivators or corepressors that will result in activating or
repressing the transcription of different genes.3 Binding of E2 activates
the ER, regulating activity. Both ERα and ERβ forms are found in
different tissue types. However, ERα is expressed more in breast tissue
and is also known to be involved in the pathway that regulates breast
cancer development.2,4 ERα antagonists such as raloxifene (Fig. 1) can
bind to ER in the same ligand-binding domain as E2, and disrupt
normal ER cellular function.4,5

Figure 1 Structures of 17β-estradiol and raloxifene.
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A key structural feature of E2 is the presence of two hydroxyl
groups that are separated by 11 Å, which permits interaction with
conserved binding site residues Arg394/Glu353 and His 524. But, the
receptor is capable of binding many other compounds whose
structures resemble that of the E2 hormone.6 Some of these
compounds are endogeneous, such as estrone and other human
estrogens; and, some are exogeneous, like the drugs raloxifene (Fig.
1) or tamoxifen that are used to treat breast cancer and osteoporosis.7
In addition to drugs, there exist other exogeneous compounds, some
naturally occurring like phytoestrogens and some synthetic such as
organochlorines, that have measurable estrogenic activity.5 Many of
these latter compounds have been shown to be linked to breast cancer
as well as birth defects.8,9 Through the National Institutes of
Environmental Health Sciences, the BSB (Biomolecular Screening
Branch), and other federal agencies, the government has developed a
program to test many of the chemicals currently in our environment,
to see if they have estrogenic activity.10
Because of the estrogen receptor’s prominent role as a breast
cancer drug target, along with the threat posed by the potentially large
number of estrogen agonists and antagonists in our environment (e.g.,
endocrine disruptors), it is essential to gain a better understanding of
the binding requirements of the ERα ligand pocket. This understanding
will allow for the design of better breast cancer drugs that interfere
with the carcinogenic activity of estrogen agonists, and improve our
ability to predict which pollutants might bind to ERα. Such predictions
are strengthened by a better definition of the molecular features that
trigger agonist or antagonist effects, as well as a validation of the
docking methods used to predict binding.
One technique that can provide a quick and reliable
experimental measurement of binding affinity is fluorescence
polarization.11 A fluorescence polarization displacement assay can be
used to screen non-fluorescent molecules, by displacing a fluorescent
probe with the molecule of interest.12 Such fluorescence polarization
displacement assays have been developed previously for ERα and ERβ,
based on a fluorescein isothiocyanate (FITC)-tagged estradiol (FE2).13,14 One such assay is available from Invitrogen.15 Subsequent
studies in our lab improved the synthesis of F-E2 and examined the in
vivo behavior of F-E2 in vivo, in fish. F-E2 was found to localize in cells
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that develop into reproductive organs, consistent with the proposed
role of E2 in gender determination in fish.16 An analogous fluorescence
polarization method was developed using an intrinsically fluorescent
nonsteroid estrogen.17
Herein we present the synthesis of a series of phenolic monoand di-hydroxyl estrogen analogs, which were tested for binding
affinity for human ERα, using a fluorescence polarization displacement
assay based on F-E2. Estrogen (E2) is a phenolic compound comprised
of a steroid core and a second hydroxyl group that is 11 Å from the
phenolic hydroxyl. Compounds synthesized herein have the phenolic
core, but vary in terms of whether they: (a) are steroid-based, and (b)
possess a second hydroxyl group, ~11 Å from the phenol. In addition
to binding affinity measurements for compounds, docking calculations
were performed. Docking is the process of positioning a ligand into the
binding site of a protein and calculating a binding energy for each
pose.18 It has become an important early-stage method for finding
molecules likely to bind to a protein, allowing for many chemicals to be
rapidly screened as potential drug leads.18–20 Docking has also proven
useful for identifying compounds as targets for pollutant remediation.21
Besides predicting relative binding affinity, docking is used to predict
the orientation or pose of a known ligand bound to a protein.22
Comparison of docking predictions with experimental affinity
measurements allows one to rationalize binding site requirements, and
also provides validation of the predictive ability of the docking
calculations for a given target (e.g., ERα) and class of compounds
(phenolic mono- and di-hydroxyl compounds). This is important
because such experimental validation provides greater confidence in
the docking calculations when they are done on larger sets of
compounds, where experimental verification might not be feasible.

2. Results and discussion
2.1. Synthesis
Wittig olefination of estrone benzyl ether,23 followed by
epoxidation with mCPBA gave the known24 epoxide 1 as a mixture of
diastereomers (Scheme 1). Deprotonation of 1 with lithium
diisopropylamine, followed by cleavage of the benzyl ether under
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dissolving metal conditions gave the allylic alcohol 2. Palladium
catalyzed alkoxycarbonylation of the vinyl triflate derived from estrone
benzyl ether, according to the literature procedure,25 gave n-propyl
(20S)-3-(phenylmethoxy)-estra-1,3,5(10),16-tetraene- 17-carboxylate
(3), which upon reduction in the presence of Raney-Ni gave the
saturated ester 4. The skipped diene (20S)-3- (phenylmethoxy)19,24-dinorchola-1,3,5(10),16,22-pentaene (5) was prepared by the
literature procedure.25 Hydrogenation of the less substituted olefin in
the presence of Wilkinson’s catalyst, followed by debenzylation gave 7.
Hydroboration–oxidation of 5, by the literature procedure26 gave
(20S)-3-(phenylmethoxy)-19,24- dinorchola-1,3,5(10),16-tetraen-23ol (8). Subjecting 8 to acid resulted in the spirocyclic tetrahydrofuran
9 in quantitative yield, which upon catalytic hydrogenolysis gave 10.
Alternatively, debenzylation of 8 afforded 11. Oxidation of 11 gave
the aldehyde 12. Reaction of 12 with an excess of methyl Grignard,
followed by work-up with saturated aqueous ammonium chloride
proceeded by cyclization to afford the spirocyclic tetrahydrofuran 13
as a mixture of diastereomers.

Scheme 1 Preparation of tetra- and pentacyclic ER analogs (ADD = 1,1′(azodicarbonyl)dipiperidine).
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A series of p-substituted phenols were also prepared (Scheme
2). Reduction of 4-(4′-hydroxyphenyl)cyclohexanone gave a separable
mixture of trans-4-(4′-hydroxy-cyclohexyl)phenol 15 (86%) and its
cis- diastereomer 14 (10%). The stereochemical assignments for each
were made by comparison to their literature spectral data.27 Reaction
of 4-(4′-hydroxyphenyl)cyclohexanone with hydroxylaminehydrochloride gave the oxime 16. [4-((4′-Hydroxyphenyl) cyclohepta2,6-dienyl)methanol 17 was prepared from p-acetoxystyrene
according to the literature procedure.28 This involved cross metathesis
with (1-methoxycarbonyl-2-vinyl-3-pentene- 1,5-diyl)Fe(CO)3 (21),
followed by oxidatively induced reductive elimination. Reduction of the
resultant cyclopropane-carboxylate and concomitant Cope [3,3]rearrangement gave the cycloheptadiene 17. Catalytic reduction of 17
gave the saturated cycloheptane 18. Finally, Heck-type coupling of
methyl 5-bromo- 2-furanoate with p-acetoxystyrene gave the transstyrylfuranoate 19, which upon reduction with lithium aluminum
hydride gave the furfuryl alcohol 20.
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Scheme 2 Preparation pf p-substituted phenols. Reagents and conditions: (a)
21,Grubbs 1st generation catalyst; (b) H2O2/NaOH; (c) LiAIH4, then 160 °C; (d) H2,
20% Pd/C, MeOH; (e) LiAIH4, Et2 O. (See above-mentioned reference for further
information.)

2.2. Fluorescence polarization displacement and cellbased ERα and ERβ luminescence activity assays
Twelve compounds from Schemes 1 and and 2 were screened
using fluorescence polarization, for their ability to bind ERα (Table 1).
Only six compounds showed any significant affinity for the receptor at
concentrations as high as 1 μM. These compounds include five of the
six steroid-core compounds—2, 4, 7, 11, and 13—and one bicyclic
compound—18. Of the remaining six compounds which did not bind to
ERα, one has the steroid core while the others contain the linked ring
cores containing a flanking hydroxyl group—a structure whose
hydrophobic interior and hydrophilic exterior resembles that of
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estrogen itself. The highest affinity ERα ligand was 2, with a Kd (32
nM) approaching that of E2 (3 nM). 18 is the only non-steroid core
compound with measurable ERα binding affinity, but an accurate Kd
could not be obtained (estimated to be >1 μM).
Table 1 Dissociation constants (Kd) from the fluorescence polarization displacement
assay and IC50 data from cell-based ERα and ERβ agonist assays and ERβ antagonist
assays

Compound ERα Kd
(nM)

ERα agonist
IC50 (nM)

ERβ agonist
IC50 (nM)

ERβ
antagonist
IC50 (nM)

E2

315

1.327

46 pM27

NA

11

320 ± 40

NA

108 ± 67

275 ± 40

4

320 ± 40

92 ± 1

9.8 ± 2

NA

7

160 ± 10

NA

88 ± 9

70 ± 15

13

160 ± 10

484 ± 1

111 ± 26

NA

2

32 ± 5

145 ± 1

6.8 ± 0.2

NA

18

>1 μM

NA

5.4 ± 0.3

137 ± 100

ERα antagonist behavior was not observed. NA indicates data was not of sufficient
quality to measure activity. Assay data for E2 binding to ERα,15 and ERα agonist and
ERβ agonist and antagonist activity in cellular assays,27 were previously reported.

Cell-based ERα and ERβ luminescence assays were performed to
determine whether the ERα ligands were acting as agonists or
antagonists, and whether they had specificity for the α isoform (Table
1, Fig. S1–6). Three compounds, 4, 13, and 2, showed agonist activity
in the ERα assay; and, all six compounds showed ERβ agonist activity,
with 4, 2, and 18 being the most potent; 18 is unique in its selectivity
for ERβ over ERα, and is 25-fold more potent as an agonist, versus
antagonist. 11, 7, and 18 displayed ERβ antagonist activity, with 7
being the most potent.

2.3. Docking
Compounds were computationally docked into human ERα and
ERβ in agonist and antagonist conformations. Poses for ERα are shown
in Fig. S7–8. Initial control docking studies were performed with E2, to
validate the docking method by demonstrating an ability to reproduce
the known binding mode from the crystal structure. Interestingly, E2
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docked with similar predicted affinity in two distinct poses for the ERα
agonist conformation (Fig. S9, Table S1), essentially flipping the
positioning of the two hydroxyl groups with regard to interactions with
Arg394/Glu353 and His524, located on opposite sides of the pocket.
The predicted pose with the phenolic hydroxyl near Arg394/Glu353 is
referred to as the ‘normal’ mode, and that with the phenolic hydroxyl
near His524 as the ‘reversed’ mode. But, if docking is performed on
receptor that has the tightly bound water present near Arg394/Glu353,
then only the expected pose is obtained; and, E2 is the ligand with
highest predicted affinity (Table 2), as expected. Thus, all docking was
performed with the Arg394/Glu353 water present. This binding mode
has been studied previously using molecular dynamics, and illustrates
the important role of active site water molecules in ligand binding.30
Table 2 Docking of compounds prepared in Schemes 1 and and22 into the agonist
and antagonist conformations of ERα and ERβ

Compound Docking
score for
ERα agonist
(kcal mol−1)

Docking score
for ERα
antagonist
(kcal mol−1)

Docking
score for
ERβ agonist
(kcal mol−1)

Docking score
for ERβ
antagonist
(kcal mol−1)

E2

−10.36

−9.70

−10.11

−9.29

4

−10.29

−10.38

−10.66

−10.13

2

−9.82

−9.86

−10.40

−9.71

11

−9.80

−9.30

−10.18

−10.28

7

−9.74

−9.37

−10.00

−10.36

10

−8.82

−9.21

−6.41

−10.08

13

−8.73

−8.82

−4.82

−9.92

18

−8.22

−7.66

−7.86

−7.48

17

−7.37

−7.10

−6.97

−6.83

16

−7.27

−6.99

−6.92

−6.96

20

−6.93

−7.20

−7.34

−7.11

15

−6.85

−6.38

−6.56

−6.77

14

−6.41

−6.28

−6.43

−6.60

Compounds identified as having ERα affinity in the fluorescence polarization
displacement assay are in bold.

Docking results were rank ordered according to the lowest
energy pose for binding to the ERα agonist conformation, from the
cluster with the highest population (Table 2). Identifying the
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compounds with measurable Kd values from the fluorescence
polarization displacement assay (shown as bold in Table 2) indicates
that the docking procedure using Autodock4 was able to separate the
binding ligands from the non-binding ligands. ER is a unique docking
target, since the binding site is comprised of a nearly closed
hydrophobic pocket, flanked by hydrogen bonding groups that could
provide specificity.31 Care in analyzing docking results is needed due to
the large binding area in which ligands can potentially bind, and
symmetry of the pocket. Three examples of reversed binding modes
that are likely false are shown in Figure 2.

Figure 2 Lowest energy docking poses from clusters where ligands were predicted
to bind in two modes (A–B). The human ERα estrogen receptor that was used was in
the agonist conformation (PDB code 1ere; chain A). Panel C shows the predicted
binding orientation for 18 in ERβ, agonist conformation (PDB code 2jj3; chain A).
Panel D shows the predicted binding orientation for 18 in ERβ, antagonist
conformation (PDB code 1l2j; chain A).

Interestingly, while estradiol docked in only one orientation
when the bound water is present, other compounds were still predicted
to bind in two orientations (Table 2; Fig. 2), one normal (with the
phenolic hydroxyl interacting with Arg394/Glu353/Water), and one
‘reversed,’ where the phenolic hydroxyl interacts with His524. This
promiscuity in predicted binding mode may be due to symmetry in diBioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and
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hydroxyl molecules like 2 (Fig. 2). Curiously, the mono-hydroxyl 4
also is predicted to bind in a reversed mode (Fig. 2), but with much
lower affinity relative to the normal mode. This is likely due to the fact
that 4 has only one hydroxyl group, the phenol, which provides
significant binding energy via interaction with the
Arg394/Glu353/water triad. It is also clear that the aliphatic hydroxyl
interaction with His524 is not essential, since it is absent in 4 and 7,
and yet both bind with reasonable affinity (IC50 = 160–320 nM).
Indeed, this observation is consistent with the ability of phenolic
endocrine disruptors, which contain only one hydroxyl group, to bind
to ER.32
The docking of compounds 10 and 13 in the ERβ-agonist
conformation displayed predicted binding energies that were weaker
than expected in Table 2. Inspection of the binding site (Fig. S10)
showed that these ligands experience steric clashes with binding site
sidechains. Additionally, for structures 10 and 13, the oxygen atom in
the tetrahydrofuran ring was not positioned near His475 for 10 or (for
reversed mode binding) near Arg346, Glu305 for 13, to allow for
hydrogen bond formation.
Compound 18 is in a unique class, in that it is not based on the
steroid core, is selective for the β over the α ER isoform, and is 25fold selective for ERβ agonist versus ERβ antagonist activity (Table 1).
Docking pose predictions (Fig. 2C and D) show that 18 could form two
hydrogen bonds (one with His475) in the ERβ agonist conformation,
whereas in the ERβ antagonist conformation, hydrogen bonding is with
Thr299, rather than His475. A molecular overlay of E2 and 18 (Fig.
S11) shows the oxygen atoms of the two molecules are well-aligned.

3. Conclusions
Human ERα remains an important target for therapeutic
interventions (cancer; osteoporosis). Estrogen has a key interaction
between its phenolic hydroxyl and a binding site Arg394/Glu353/water
triad, along with other important interactions including van der Waals
interactions with the steroid core, and hydrogen bonding interactions
between an aliphatic hydroxyl group and His524 (His475 in ERβ). The
two estradiol hydroxyls are located 11 Å from each other. The studies
presented herein probe the importance of interactions with the
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aliphatic hydroxyl and with the steroid core, using a series of novel
mono- and di-hydroxyl compounds (Schemes 1 and and22).
The estrogen analog with highest measured affinity in the
fluorescence polarization displacement assay(IC50 = 32 nM) and
second highest predicted affinity is the di-hydroxyl steroid 2, which
has a single point of unsaturation in the D-ring, and (relative to
estradiol) has its aliphatic hydroxyl extended by one methylene group.
Nonetheless, this gives an O–O distance essentially equivalent to that
for estradiol. Di-hydroxyl steroid 2 behaves as an ERα agonist, and
has no selectivity for α versus β ER isoforms. Indeed, 2 is a potent ERβ
agonist and antagonist. In contrast, 18 binds weakly to ERα, yet has
on O–O distance (11.1 Å) that is similar to 2. Of particular interest is
the fact that 18 has the expected interaction with His475 in the ERβ
agonist docking, whereas in the ERβ antagonist docking this aliphatic
hydroxyl group is predicted to interact instead with Thr299 (Fig. 2).
This could explain why 18 is so selective (25-fold) as an ERβ agonist,
versus as an antagonist (Table 1). Most of the other compounds from
Scheme 2 that lacked the steroid core did not bind to ERα, even
though they possessed the phenolic hydroxyl. Compounds (4, 13, 2),
which possessed ERα agonist activities, were also ERβ agonists; but,
not ERβ antagonists. And, these compounds were more selective for
ERβ over ERα.
In summary, several compounds have been identified that are
potent ERα agonists, and also behave as ERβ agonists and antagonists
(Table 1). The most potent is the dihydroxyl steroid 2. Also, the nonsteroid dihydroxyl compound 18 is 1000-fold more selective for ERβ
over ERα, and appears to adopt a different binding mode in these two
targets (Fig. 2).

4. Experimental
4.1. General methods
The β-estradiol (min 98%) and fluorescein (FITC) were
purchased from Sigma. The α-ER and α-ER screening buffer were from
Invitrogen. The FITC-estradiol linked tracer used in the experiments
was synthesized by as described previously. (1) DMSO-d6 was
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purchased from Cambridge Isotopes. The 96-well plates used were
black, polystyrene, NBS (non-binding surface), flat-bottom plates
obtained from Corning. A PolarStar Galaxy fluorescent plate reader
was used and controlled with FLUOStar Galaxy software (version 4.300). Estrone benzyl ether23 and compounds 3,25 5,26 8,26 and 1728 were
prepared by the literature procedures.

4.2. Estrogen analog synthesis
4.2.1. 3-Hydroxyestra-1,3,5(10),16-tetraene-17-methanol (2)
To a solution of methyl triphenylphosphonium bromide (589 mg,
1.65 mmol) in THF (10 mL) at −40 °C under N2, was added a solution
of n-butyl lithium (0.66 mL, 2.5 M in hexanes, 1.7 mmol). The ylide
solution was warmed to room temperature and a solution of estrone
benzyl ether (200 mg, 0.556 mmol) in THF (7 mL) was added. The
mixture was stirred for 12 h, and then heated at reflux for 5 h. The
solution was cooled, and concentrated, and the residue was purified by
column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to afford
the exocyclic methylene product (168 mg, 84%) as a colorless solid.
This product was used in the next step without further
characterization. To a solution of the olefin (100 mg, 0.279 mmol) in
dichloromethane (6 mL) at 0 °C, was added solid mchloroperoxybenzoic acid (57.5 mg, 0.333 mmol). The reaction
mixture was 4 h, and then quenched with aqueous NaHCO3. The
mixture was extracted several times with dichloromethane, dried and
concentrated to afford the epoxide 1 (90 mg, 86%) as a colorless oil,
which was used in the next step without further purification. To a
solution of the epoxide (50 mg, 0.13 mmol) in hexanes (1 mL) and
toluene (0.5 mL) was added HMPA (1 drop). The mixture was cooled to
−78 °C, and then a solution of lithium diisopropylamine in hexanes
(0.73 mmol) was added. The solution was warmed to room
temperature and stirred for 10 h. The mixture was quenched with
saturated aqueous NH4Cl, and the mixture extracted several times with
ether. The combined extracts were dried (MgSO4) and concentrated,
and the residue was purified by column chromatography (SiO2,
hexanes–ethyl acetate = 3:2) to afford a colorless oil (29 mg, 58%)
which was used without further characterization. To liquid ammonia
(ca. 10 mL), at −78 °C was added lithium metal (24 mg, 3.5 mmol),
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followed by t-butyl alcohol (0.05 mL). To this solution was added a
solution of the allylic alcohol (20 mg, 0.053 mmol) in THF (1 mL). The
reaction mixture was stirred at −78 °C for 15 min, and then quenched
with NH4Cl, and diluted with ether. The mixture was warmed to room
temperature, and water (10 mL) was added. The mixture was
extracted several times with ether followed by extraction with
dichloromethane. The combined extracts were dried (MgSO4),
concentrated and the residue was purified by column chromatography
(SiO2, hexanes–ethyl acetate = 3:2) to afford 2 (9.0 mg, 60%) as a
colorless solid. Mp 192–194 °C; 1H NMR (CDCl3, 400 MHz) δ 7.15 (d, J
= 8.4 Hz, 1H), 6.64 (dd, J = 2.8, 8.4 Hz, 1H), 6.58 (d, J = 2.8 Hz,
1H), 5.65 (dd, J = 1.2, 2.8 Hz, 1H), 4.80 (br s, OH), 4.32–4.25 (m,
2H), 2.95–2.80 (m, 2H), 2.40–1.70 (m, 11 H), 0.87 (s, 3H); 13C NMR
(CDCl3, 100 MHz) δ 155.2, 153.5, 138.5, 133.1, 126.4, 124.3, 126.4,
124.3, 115.5, 112.8, 60.4, 56.8, 46.4, 44.6, 37.4, 34.8, 31.1, 29.7,
27.9, 26.6, 16.5.

4.2.2. n-Propyl 3-hydroxyestra-1,3,5(10)-triene-17-carboxylate
(4)
To a solution of 3 (177 mg, 0.411 mmol) in ethanol (10 mL)
was added an aqueous slurry of Raney-Ni (60%, 0.6 mL). The reaction
mixture was stirred under a H2 gas (balloon pressure) for 24 h, after
which the mixture was filtered through a bed of filter-aid. The filter
bed was washed several times with ethyl acetate, and the filtrate was
concentrated under reduced pressure to afford 4 as a colorless solid
(129 mg, 92%): mp 151.5–153 °C, [α]20D +69.5 (c 0.388, CHCl3); 1H
NMR (CDCl3, 300 MHz) δ 7.17 (d, J = 8.4 Hz, 1H), 6.64 (dd, J = 2.8,
8.5 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 4.55 (br s, OH), 4.10 (dt, J =
10.8, 6.7 Hz, 1H), 4.02 (dt, J = 10.8, 6.7 Hz, 1H), 2.90–2.80 (m, 2H),
2.44 (t, J = 9.3 Hz, 1H), 2.35–2.15 (m, 3H), 1.90–1.75 (m, 3H), 1.68
(sextet, J = 7.2 Hz, 2H), 1.55–1.30 (m, 7H), 0.98 (t, J = 7.3 Hz, 3H),
0.71 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 174.5, 153.5, 138.4, 132.8,
126.7, 115.4, 112.8, 66.0, 55.6, 55.1, 44.3, 43.9, 39.0, 38.6, 29.8,
27.8, 26.7, 24.3, 23.7, 22.3, 13.7, 10.9. Anal. Calcd for
C22H30O3·1/2H2O: C, 75.18; H 8.89. Found: C, 75.36; H, 8.28.
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4.2.3. (20S) 3-(Phenylmethoxy)-19,24-dinorchola-1,3,5(10),16tetraene (6)
To a solution of 5 (0.20 g, 0.50 mmol) in benzene (10 mL) in a
Schlenk flask was added Rh(PPh3)3Cl (40 mg, 0.043 mmol). The
reaction mixture was cooled with a dry ice–acetone bath, evacuated
under high vacuum, and the system refilled to 1 atm with H2 gas. The
mixture was stirred for 7 h at room temperature, and then the solvent
was evaporated. The residue was extracted several times with ether,
filtered, and concentrated. The residue was purified by column
chromatography (SiO2, hexanes–CH2Cl2 = 10:1) to afford 6 (138 mg,
69%) as a colorless solid. Mp 82–83.5 °C, [α]20D +67 (c 0.74,
acetone); 1H NMR (CDCl3, 300 MHz) δ 7.46–7.30 (m, 5H), 7.20 (d, J =
8.4 Hz, 1H), 6.78 (br d, J = 8.4 Hz, 1H), 6.74 (br s, 1H), 5.35 (br s,
1H), 5.04 (s, 2H), 2.94–2.84 (m, 2H), 2.40–2.08 (m, 4H), 2.00–1.87
(m, 3H), 1.65–1.28 (m, 7H), 1.09 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 7.3
Hz, 3H), 0.83 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 160.2, 155.9,
137.6, 136.7, 132.9, 128.0, 127.3, 127.0, 125.6, 120.4, 114.4, 111.8,
70.0, 56.4, 47.8, 44.7, 37.8, 35.4, 33.6, 31.3, 30.3, 30.2, 28.2, 27.0,
21.3, 17.1, 12.4. Anal. Calcd for C29H36O: C, 86.95; H, 9.06. Found: C,
86.99; H, 9.12.

4.2.4. (20S) 3-Hydroxy-19,24-dinorchola-1,3,5(10),16-tetraene
(7)
Cleavage of the benzyl ether 6 (73 mg, 0.18 mmol) with sodium
metal in n-butanol was carried out in a fashion similar to the cleavage
of 8. Purification of the residue by column chromatography (SiO2,
hexanes–ethyl acetate gradient = 5:1) gave unreacted starting
material (17 mg) followed by 7 (46 mg, 81%) as a colorless solid. Mp
92–95 °C, [α]20D +86.3 (c 0.32, acetone); 1H NMR (acetone-d6) δ
7.05 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 2.1, 8.4 Hz, 1H), 6.51 (d, J =
2.1 Hz, 1H), 5.35 (br s, 1H), 2.82–2.73 (m, 2H), 2.37–2.28 (m, 1H),
2.22–2.05 (m, 2H), 1.97–1.85 (m, 4H), 1.60–1.26 (m, 8H), 1.07 (d, J
= 7.2 Hz, 3H), 0.87 (t, J = 7.5 Hz, 3H), 0.82 (s, 3H); 13C NMR
(acetone-d6) δ 162.5, 156.7, 139.3, 133.2, 127.7, 122.7, 117.1,
114.7, 58.8, 50.0, 47.1, 40.4, 37.7, 35.8, 33.4, 32.5, 32.2, 30.6,
29.3, 23.2, 19.0, 14.1. Anal. Calcd for C22H30O·1/6H2O: C, 84.28; H,
9.75. Found: C, 84.28; H, 9.82.
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4.2.5. (20S) 3-Hydroxy-19,24-Dinorchola-1,3,5(10),16-tetraen23-ol (11)
To a solution of 8 (394 mg, 0.947 mmol) in n-butanol (20 mL),
at 70 °C, was added sodium metal (0.87 g, 38 mmol) in small pieces.
After all of the sodium had reacted, the reaction mixture was cooled to
room temperature and quenched with water, followed by saturated
aqueous NH4Cl. The reaction mixture was extracted several times with
ether, the combined extracts were dried (MgSO4) and concentrated.
The residue was purified by column chromatography (SiO2, hexanes–
ethyl acetate gradient = 4:1 to 2:1) to afford unreacted starting
material (91 mg) followed by 11 (150 mg, 49%) as a colorless solid.
Mp 174.5–176 °C, [α]20D +77.5 (c 1.50, acetone); 1H NMR (acetoned6) δ 8.15 (s, phenol OH), 7.04 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 2.7,
8.4 Hz, 1H), 6.51 (d, J = 2.7 Hz, 1H), 5.38 (br s, 1H), 3.64–3.52 (m,
3H), 2.84–2.74 (m, 2H), 2.42–2.28 (m, 2H), 2.20–2.08 (m, 1H),
1.96–1.70 (m, 4H), 1.60–1.30 (m, 7H), 1.10 (d, J = 7.2 Hz, 3H), 0.82
(s, 3H); 13C NMR (acetone-d6) δ 162.8, 156.6, 139.2, 133.0, 127.6,
122.6, 117.0, 114.6, 61.4, 58.7, 49.9, 47.0, 43.0, 40.3, 37.5, 33.2,
32.0, 30.9, 30.5, 29.2, 23.7, 19.0. Anal. Calcd for C22H30O2: C, 80.94;
H, 9.26. Found: C, 80.67; H, 9.32.

4.2.6. 17,23-Epoxy-3-(phenylmethoxy)-19,24-dinorchola1,3,5(10)-triene (9)
To a solution of 8 (56 mg, 0.14 mmol) in CHCl3 (2 mL) was
added a drop of concentrated HCl. The mixture was allowed to stand
stirred for 24 h at room temperature, and then passed through a short
column of silica gel using hexanes–ethyl acetate as eluent.
Concentration of the eluent gave 9 (50 mg, 89%) as a colorless oil.
[α]20D +36 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz) δ 7.46–7.28
(m, 5H), 7.22 (d, J = 8.4 Hz, 1H), 6.87 (dd, J = 2.7, 8.4 Hz, 1H), 6.73
(d, J = 2.7 Hz, 1H), 5.04 (s, 2H), 3.87 (dt, J = 4.5, 7.8 Hz, 1), 3.62
(dt, J = 6.4, 7.8 Hz, 1H), 2.92–2.82 (m, 2H), 2.38– 1.20 (m, 16H),
1.10 (d, J = 6.9 Hz, 3H), 0.74 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ
155.8, 137.6, 136.7, 132.8, 128.2, 127.3, 126.9, 125.8, 114.4, 111.8,
95.5, 70.0, 66.0, 50.0, 48.2, 44.0, 39.3, 36.9, 35.1, 31.3, 31.0, 30.3,
28.1, 26.6, 23.6, 19.0, 15.8. Anal. Calcd for C29H36O2: C, 83.61; H
8.71. Found: C, 83.35; H, 8.75.
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4.2.7. 17,23-Epoxy-3-hydroxy-19,24-dinorchola-1,3,5(10)triene (10)
To a solution of 9 (48.9 mg, 0.118 mmol) in methanol/CHCl3
(1:100, 6 mL) was added 10% Pd on carbon (5.6 mg). The mixture
was stirred under H2 (ca. 46 psi) in a Paar hydrogenation apparatus for
3 h. The catalyst was removed by filtration through filter-aid and the
filter bed was washed with copious CH2Cl2 and the combined filtrates
were concentrated. The residue was purified by chromatography (SiO2,
hexanes–ethyl acetate = 3:1) to afford 10 as a colorless solid (37.8
mg, 99%). Mp 172–174 °C; 1H NMR (CDCl3, 300 MHz) δ 7.15 (d, J =
8.4 Hz, 1H), 6.62 (dd, J = 2.7, 8.4 Hz, 1H), 6.55 (d, J = 2.7 Hz, 1H),
3.87 (dt, J = 4.5, 7.8 Hz, 1H), 3.60 (dt, J = 6.3, 8.1 Hz, 1H), 2.85–
2.75 (m, 2H), 2.35–1.20 (m, 16H), 1.07 (d, J = 6.9 Hz, 3H), 0.70 (s,
3H); 13C NMR (CDCl3, 75 MHz) δ 153.3, 138.6, 133.2, 126.6, 115.4,
112.7, 96.0, 66.1, 50.0, 48.2, 43.9, 39.3, 36.8, 35.0, 31.2, 30.8,
30.0, 27.9, 26.4, 23.4, 18.8, 15.6. Anal. Calcd for C22H30O2·1/4H2O: C,
79.83; H 9.29. Found: C, 80.12; H, 9.33.

4.2.8. (20S) 3-Hydroxy-19,24-dinorchola-1,3,5(10),16-tetraen23-al (12)
To a solution of 11 (100 mg, 0.296 mmol) in THF (4 mL) was
added a solution of ethyl magnesium bromide in THF (0.67 mL, 1.0 M,
0.67 mmol). The solution was stirred at room temperature for 15 min,
and then solid 1,1′-(azodicarbonyl)dipiperidine (0.17 g, 0.67 mmol)
was added. The reaction mixture was stirred for 1 h, and then
quenched with saturated aqueous NH4Cl and extracted several times
with ether. The combined ethereal extracts were dried (MgSO4),
concentrated and the residue was purified by column chromatography
(SiO2, hexanes–ethyl acetate = 5:1) to afford 12 as a colorless solid
(66 mg, 66%). Mp 168.5–171 °C, [α]20D +78 (c 0.80, acetone); 1H
NMR (acetone-d6, 300 MHz) δ 9.66 (t, J = 2.1 Hz, 1H), 7.06 (d, J =
8.4 Hz, 1H), 6.57 (dd, J = 2.5, 8.4 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H),
5.46 (br s, 1H), 2.90–2.75 (m, 4H), 2.62 (ddd, J = 1.8, 5.7, 16.2 Hz,
1H), 2.44–2.30 (m, 2H), 2.26–2.10 (m, 2H), 1.98–1.86 (m, 3H),
1.60–1.34 (m, 5H), 1.16 (d, J = 7.2 Hz, 3H), 0.88 (s, 3H); 13C NMR
(acetone-d6, 75 MHz) δ 203.2, 161.4, 156.8, 139.5, 133.3, 127.9,
124.6, 117.2, 114.8, 59.2, 53.1, 50.2, 47.2, 40.5, 37.7, 33.6, 32.3,
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30.7, 29.7, 29.4, 23.8, 19.3. Anal. Calcd for C22H28O2: C, 81.44; H,
8.70. Found: C, 81.21; H, 8.54.

4.2.9. 17,23-Epoxy-3-hydroxy-19-norchola-1,3,5(10)-triene
(13)
To a solution of 12 (45.9 mg, 0.142 mmol) in THF (7 mL) at
0 °C was added a solution of methyl magnesium bromide in ether
(0.10 mL, 3.0 M, 0.30 mmol). The reaction mixture was stirred for 3 h,
and then quenched with saturated aqueous NH4Cl (15 mL). The
mixture was extracted several times with CH2Cl2 and the combined
extracts were dried (MgSO4) and concentrated. The residue was
purified by chromatography (SiO2, hexanes–ethyl acetate = 5:1) to
afford 13 as a colorless solid (44 mg, 92%). Analysis of the product by
1
H NMR spectroscopy indicated this to be a 1:1 mixture of
diastereomers. Mp 248–251 °C, 1H NMR (CDCl3, 300 MHz) δ 7.15 (d, J
= 8.4 Hz, 1H), 6.62 (dd, J = 2.7, 8.4 Hz, 1H), 6.56 (d, J = 2.7 Hz,
1H), 4.18–4.07 (m, 1H), 3.85–3.74 (m, 1H), 2.85–2.75 (m, 2H),
2.35–1.20 (m, 15H), 1.23 & 1.20 (2 × d, J = 5.7 Hz, 3H total), 1.07 &
1.05 (2 × d, J = 6.9 Hz, 3H), 0.72 & 0.66 (2 × s, 3H total); 13C NMR
(CDCl3, 75 MHz) δ 153.3, 138.6, 133.2, 126.6, 115.4, 112.7, 97.1
[95.8], 73.6 [71.3], 49.85 [49.80], 48.8, 47.1, 45.4, 43.9 [43.8],
43.5, 39.3 [39.2], 36.2, 34.5, 32.3, 31.2 [30.9], 30.6 [30.1], 27.8,
26.5 [26.4], 23.5 [23.4], 21.6, 19.2 [18.9], 16.3 [14.9]. Anal. Calcd
for C23H32O2·1/2H 2O: C, 79.04; H, 9.52. Found: C, 79.34; H, 9.57.

4.2.10. cis- and trans-4-(4′-Hydroxycyclohexyl)phenol (14)
To a solution of 4-(4′-hydroxyphenyl)cyclohexanone (50 mg,
0.26 mmol) in methanol (1 mL) was added NaBH4 (15 mg, 4.0 mmol).
The reaction mixture was stirred for 30 min, and then diluted with
water. The mixture was extracted several times with ethyl acetate and
the combined extracts were concentrated and purified by column
chromatography (SiO2, hexanes–ethyl acetate = 2:1) to afford cis-14
(5.0 mg, 10%) followed by trans-15 (43 mg, 86%) both as colorless
solids. Cis-14: 1H NMR (CD3OD, 400 MHz) δ 7.04–6.69 (AA′BB′, JAB =
8.8 Hz, 4H), 4.02 (narrow t, J = 2.8 Hz, 1H), 2.50–2.40 (m, 1H),
1.91–1.79 (m, 4H), 1.69–1.52 (m, 4H); 13C NMR (CD3OD, 75 MHz) δ
156.5, 140.1, 128.8, 116.1, 66.5, 44.5, 34.0, 29.4. Trans-15: 1H NMR
(CD3OD, 400 MHz) δ 7.01–6.68 (AA′BB′, JAB = 8.4 Hz, 4H), 3.58 (tt, J
Bioorganic & Medicinal Chemistry, Vol. 22, No. 1 (January 1, 2014): pg. 303-310. DOI. This article is © Elsevier and
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

19

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

= 4.4, 10.6 Hz, 1H), 2.39 (tt, J = 3.5, 11.8 Hz, 1H), 2.06–1.99 (m,
2H), 1.87–1.79 (m, 2H), 1.56–1.33 (m, 4H).

4.2.11. 4-(4-Hydroxyphenyl)-cyclohexanone oxime (16)
To a solution of 4-(4′-hydroxyphenyl)cyclohexanone (50 mg,
0.26 mmol), hydroxylamine hydrochloride (36.6 mg, 0.526 mmol) in
ethanol (5 mL) was added Amberlyst (56 mg). After stirring for 2 h,
the mixture was filtered, and the filtrate concentrated. The residue
was partitioned between water and ethyl acetate, and the organic
layer was concentrated and dried to give (±)-16 (44 mg, 82%) as a
colorless solid. Mp 172–175 °C. 1H NMR (CD3OD, 400 MHz) δ 7.03–
6.69 (AA′BB′, JAB = 8.8 Hz, 4H), 4.02 (narrow t, J = 2.8 Hz, 1H), 2.0–
2.40 (m, 1H), 1.91–1.79 (m, 4H), 1.69–1.52 (m, 4H); 13C NMR
(CD3OD, 75 MHz) δ 161.0, 156.8, 138.4, 128.7, 116.3, 44.3, 36.0,
34.7, 33.0, 25.2. HRMS (ESI): m/z calcd for C12H15NO2+Na+ [M+Na]+
228.0995, found 228.0997.

4.2.12. cis-1-Hydroxymethyl-4-(4′-hydroxyphenyl)-cycloheptane
(18)
To a solution of (±)-17 (75 mg, 0.35 mmol) in methanol (15
mL) in a heavy walled reaction vessel, was added a catalytic amount
of 20% Pd/C. The mixture was stirred under H2 pressure (45 psi) for
75 min and then the reaction mixture was filtered through the pad of
celite. The filtrate was concentrated and the residue was purified by
column chromatography (SiO2, hexanes–ethyl acetate = 65:35) to
afford (±)-18 (38 mg, 50%) as a colorless solid. Mp 60–61 °C; 1H
NMR (CDCl3, 300 MHz) δ 7.06 and 6.75 (AA′BB′, JAB = 9.0 Hz, 4H),
3.48 (d, J = 6.3 Hz, 1H), 2.59–2.58 (m, 1H), 1.95– 1.08 (m, 13H); 13C
NMR (CD3OD, 75 MHz) δ 127.9, 115.3, 68.6, 46.1, 41.4, 38.8, 33.1,
31.6, 28.5, 27.5. HRMS (ESI): m/z calcd for C14- H20O2+Na+ [M+Na]+
243.1356, found 243.1356.

4.2.13. 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-2-furanmethanol
(20)
A solution of methyl 5-bromo-2-furanoate (1.03 g, 5.02 mmol),
4-acetoxystyrene (0.97 g, 6.0 mmol), palladium acetate (0.01 g, 0.05
mmol), tri-o-tolylphosphine (0.03 g, 0.2 mmol), and triethylamine (3
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mL) was heated under nitrogen in a sealed heavy-walled Pyrex tube at
100 °C for 24 h. The reaction mixture was cooled, diluted with water
and dichloromethane. The dichloromethane layer was separated,
washed with water, and dried (MgSO4), and the residue was purified
by column chromatography (SiO2, hexanes–ethyl acetate = 4:1) to
afford 19 (350 mg, 24%), a pale yellow solid. Mp 110.5–112 °C; 1H
NMR (CDCl3, 300 MHz) δ 7.51 (d, J = 8.1, 2H), 7.27 (d, J = 16.5 Hz,
1H), 7.20 (d, J = 3.6 Hz, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.86 (d, J =
16.5 Hz, 1H), 6.45 (d, J = 3.6 Hz, 1H), 3.92 (s, 3H, OMe), 2.32 (s, 3H,
OAc). This product was used in the next step without further
characterization. To a solution of diester (50 mg, 0.17 mmol) in
anhydrous ether (1 mL) at 0 °C, was slowly added a solution of lithium
aluminium hydride (0.52 mL, 1.0 M in THF, 0.52 mmol). Solution was
stirred for 3 h at 0 °C and then saturated aqueous sodium bicarbonate
(2 mL) was added follow by dilute sodium hydroxide. The mixture was
warmed to room temperature, extracted several times with ethyl
acetate. The combined extracts were dried (MgSO4), concentrated and
the residue was purified by column chromatography (SiO2, hexanes–
ethyl acetate = 1:1) gave 20 (28 mg, 74%) as a colorless solid. Mp
129–131 °C; 1H NMR (acetone- d6, 300 MHz) δ 8.59 (br s, 1H), 7.40
(d, J = 9.0 Hz, 2H), 6.97– 6.79 (m, 4H), 6.30 (s, 2H), 4.57 (br s, 2H),
3.05 (br s, 1H); 13C NMR (acetone-d6, 75 MHz) δ 158.2, 155.9, 154.1,
129.7, 128.6, 127.4, 116.5, 114.9, 109.9, 109.4, 57.4. HRMS (ESI):
m/z calcd for C13H12O3+Na+ [M+Na]+ 239.0679, found 239.0681.

4.3. Fluorescence polarization
The assay was developed based on a commercially available kit
from Invitrogen.15 Assays were run on a BMG POLARstar Galaxy reader
with acquisition parameters as follows: 200 flashes, positioning delay
1.0 s, K factor ≤ 1.1 and ≥ 0.9, excitation filter of 485 ± 5 nm and
emission filter of 520 ± 15 nm. For the IC50 determinations the [ER-α]
was 30 nM and the [FITC-estradiol tracer] ([Tr]) was 10 nM. Sample
volume was 150 μL. For each experiment the polarization was
calibrated with a sample of FITC set at 20 mP. All proper blanks were
used, including water for the FITC samples and blank samples
containing only 30 nM ERα protein for the remaining data points. All
protein samples contained 1% DMSO-d6, the maximum amount
tolerated as stated by the supplier of the ERα protein, Invitrogen, to
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ensure the solubility of all hydrophobic compounds investigated. The
Kd of the FITC-tagged estradiol for ER-α was determined by non-linear
least squares fitting of the titration curve data to the following
equation (where Tro is the F-E2 tracer):
FPmax
(Kd+[Tr0]+[ERα])
2[Tr0]
−{(Kd+[Tr0]+[ERα])2−4[Tr0]}+[ERα]
ΔFP=

4.4. Cell-based ERα and ERβ assays
ERα and ERβ assay kits for cell-based assays (Indigo
Biosciences) allowed for investigation into the functional activity (i.e.,
agonist and/or antagonist) of the ligands identified to bind based on
the initial fluorescence polarization displacement assay. Briefly, the
cells contained a luciferase reporter gene that was functionally linked
to either the ERα or ERβ-responsive promoter. By quantifying the
luciferase expression via luminescence, the change in ER activity could
be quantified. 1–2 mM stocks of the ligands were prepared in DMSO-d6
and diluted to final concentrations ranging from 3.2 nM to 2 μM, using
the Compound Screening Medium provided in the kit. For the agonist
assay, the cells were prepared by warming to 37 °C, plated, then the
chemicals added. For the antagonist assay, the cells were prepared as
above with the addition of E2 (for ERα 3.2 nM was added,
approximating an IC75; and, for ERβ 160 pM was added, approximating
an IC80). The cells were then plated, and the chemicals added. All
plates were incubated in a cell culture incubator at 37 °C and 5% CO2
for 22 h. Each assay was performed in duplicate. Luminescence was
characterized after removal of the incubating media and introduction
of the Detection Substrate using a Molecular Devices SpectraMax M5
microplate reader. Data was fitted using GraphPad Prism and fit to the
dose-response (four paramter) equation as follows.
y=

bottom−(top−bottom)
(1+10(logIC50−x)Hillslope)
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4.5. Molecular docking
Ligand structures were drawn in PC Spartan Plus (Wavefunction)
and three dimensional (3D) conformation was then optimized using
semiempirical Austin Model 1 (AM1) calculations. Since compound 13
was afforded as a pair of diastereomers both were modeled and
docked. The AM1 calculations provided geometries and bond distances
for subsequent docking. AutoDock Tools (ADT) was used prepare the
ligand files according to AutoDock requirements and assign Gasteiger
charges.
The ERα receptor for agonist (pdb code 1ere)4 and antagonist
(pdb code 1err)32 conformations were prepared for docking
calculations using the ‘A’ chain. The ERβ receptor for agonist (pdb code
2jj3)33 and antagonist (pdb code 1l2j)34 conformations were prepared
for docking calculations using the ‘A’ chain. ADT was used to further
prepare the ER receptor files by adding hydrogen atoms and adding
partial charges to each atom of the protein. The grid box was centered
on the co-crystallized ligand, drawn to a box to incorporate amino
acids Arg394, Glu353, and His524 for ERα and Arg346, Glu305, and
His475 for ERβ, then the estradiol ligand was removed.35 AutoDock (v.
4.2) calculations were performed with default parameters, except with
100 genetic algorithmic runs and 2,500,000 evaluations per run.35–39
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Footnotes
A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.bmc.2013.11.024.
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Supplementary Material 1

Supplementary Figure S1. Cell-based ERα assay data including regression for
ligands that showed agonist activity.

Supplementary Figure S2. Cell-based ERα agonist assay data for chemicals without
sufficient quality data to determine activity.
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Supplementary Figure S3. Cell-based ERα antagonist assay data for chemicals
without sufficient quality data to determine activity.

Supplementary Figure S4. Cell-based ERβ agonist assay data. for ligands that
showed antagonist activity
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Supplementary Figure S5. Cell-based ERβ assay data for chemicals that showed
antagonist activity.

Supplementary Figure S6. Cell-based ERβ assay data for chemicals that did not
display antagonist activity.
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Supplementary Figure S7. Lowest energy docking poses for the ERα-binding
compounds identified using fluorescence polarization. PDB file 1ere, chain A was used
as the receptor to investigate the predicted affinity for binding in the ERα agonist
conformation. Note: E2 is estradiol and provided for comparison.

Supplementary Figure S8. Lowest energy docking poses for the ERα-binding
compounds identified using fluorescence polarization. PDB file 1ere, chain A was used
as the receptor to investigate the predicted affinity for binding in the ERα agonist
conformation. Note: chemical 13 was docked using both enantiomers from the
racemic mixture.
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Supplementary Figure S9. Estradiol docked into PDB file 1ere, chain A with removal
of all water molecules. Black is the binding mode associated with the crystal structure
(normal). Gray is a 180° rotation of the estradiol (reversed).

Supplementary Figure S10. ERβ agonist conformation (purple) with cocrystalized
ligand (green) and docking pose predictions of 10 (blue) and 13 (yellow).
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Supplementary Figure S11. Overlay of estradiol (black) and 18 (yellow).
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Supplementary Table S1. Docking results for the agonist conformation of ER in
the absence of all water molecules.

Compound

Number of
Clusters
(2.0Å rmsd)

Lowest
Energy
Cluster
Population

Calculated
Binding
Energy (kcal
mol-1)

Mode

estradiol

2

69

-10.74

reversed

31

-10.72

normal

64

-11.09

reversed

36

-10.71

normal

estradiol
4

2

4
2

1

100

-10.98

reversed

7

2

56

-9.93

reversed

44

-9.79

normal

69

-10.35

reversed

11

29

-9.28

normal

11

2

-9.16

reversed

96

-9.48

reversed

4

-9.08

normal

7
11

10

3

2

10
13a

1

100

-7.44

normal

13b

1

100

-9.13

reversed

17

3

22

-7.27

reversed

17

76

-7.21

reversed

17

2

-7.12

normal

20

1

100

-7.57

reversed

18

2

85

-7.42

reversed

15

-7.34

normal

97

-6.71

normal

3

-6.39

reversed

73

-6.85

normal

27

-6.77

reversed

71

-7.42

reversed

16

28

-7.33

normal

16

1

-7.17

normal

18
14

2

14
15

2

15
16

3
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Supplementary Table S2. Docking results for the agonist conformation of ER in
the presence of a single water molecule near Arg294 and Glu353 as observed in the
crystal structure. Chemicals 20 and 14 were not predicted to bind similarly to the
normal or reversed modes as otherwise noted.

Compound

Number of
Clusters
(2.0Å rmsd)

Lowest
Energy
Cluster
Population

Calculated
Binding
Energy
(kcal mol1)

Mode

estradiol

1

100

-10.36

normal

4

2

97

-10.29

normal

2

2

42

-10.16

reversed

2

2

58

-9.82

normal

11

1

100

-9.80

normal

7

1

100

-9.74

normal

10

1

100

-8.82

normal

13b

1

100

-8.73

normal

13a

1

100

-8.39

normal

4

2

3

-7.73

reversed

18

2

72

-7.56

reversed

18

2

28

-7.46

normal

17

2

13

-7.46

reversed

17

2

87

-7.37

normal

16

2

97

-7.27

normal

15

2

73

-7.00

reversed

16

2

3

-6.94

reversed

20

4

76

-6.93

other

15

2

27

-6.85

normal

14

3

79

-6.41

other
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